{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:55Z","timestamp":1793305315241,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejpb.2025.114780","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:27:10Z","timestamp":1749320830000},"page":"114780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery"],"prefix":"10.1016","volume":"214","author":[{"given":"Adarsh","family":"Malgave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sideequl","family":"Akbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anumol","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dande Aishwarya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramalingam","family":"Peraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1435-6115","authenticated-orcid":false,"given":"Rajkumar","family":"Malayandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpb.2025.114780_b0005","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2025.114780_b0010","article-title":"A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography-high resolution mass spectrometry","author":"Badgujar","year":"2024","journal-title":"J. Pept. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114780_b0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3390\/biom14030264","article-title":"Exploring FDA-approved frontiers: Insights into natural and engineered peptide analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and \u03b1-MSH realms","volume":"14","author":"Al Musaimi","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejpb.2025.114780_b0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Frontiers in endocrinology"},{"key":"10.1016\/j.ejpb.2025.114780_b0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jpba.2014.06.012","article-title":"Related impurities in peptide medicines","volume":"101","author":"D\u2019Hondt","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.ejpb.2025.114780_b0030","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1080\/19420862.2017.1347741","article-title":"Biosimilarity under stress: a forced degradation study of Remicade\u00ae and RemsimaTM","volume":"9","author":"Pisupati","year":"2017","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114780_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10989-024-10608-8","article-title":"Forced degradation products of liraglutide: A comparative study of similarity between originator and analogue version by liquid chromatography\u2013mass spectrometry","volume":"30","author":"Chavoshi","year":"2024","journal-title":"Int. J. Pept. Res. Ther."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114780_b0040","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4155\/tde.14.111","article-title":"Challenges in the delivery of peptide drugs: an industry perspective","volume":"6","author":"Lewis","year":"2015","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2025.114780_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2025.116682","article-title":"Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology","volume":"256","author":"Kim","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114780_b0050","unstructured":"E. P\u0159\u00e1da, \u201cSelf-assembly and aggregation of glucagon-like peptide 1 and its analogues.\u201d University of Cambridge, 2023. https:\/\/doi.org\/10.17863\/CAM.98055."},{"key":"10.1016\/j.ejpb.2025.114780_b0055","unstructured":"Moeller, \u201cGLP-1 compositions and uses thereof,\u201d Jan. 2020. Accessed: Apr. 08, 2025. [Online]. Available: https:\/\/www.basf.com\/."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114780_b0060","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/biomedicines11082127","article-title":"Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins","volume":"11","author":"Gumieniczek","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.ejpb.2025.114780_b0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/jps.22812","article-title":"Forced degradation of therapeutic proteins","volume":"101","author":"Hawe","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114780_b0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.4155\/bio.11.31","article-title":"Peptide and protein drug analysis by MS: challenges and opportunities for the discovery environment","volume":"3","author":"Campbell","year":"2011","journal-title":"Bioanalysis"},{"key":"10.1016\/j.ejpb.2025.114780_b0075","article-title":"Journal of Pharmaceutical and Biomedical Analysis Peptide mapping analysis of synthetic semaglutide and liraglutide for generic development of drugs originating from recombinant DNA technology","volume":"256","author":"Hyun","year":"2025","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2025.114780_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123688","article-title":"Novel LC-MS\/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats","volume":"1221","author":"Lee","year":"2023","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejpb.2025.114780_b0085","unstructured":"M. T. A. Scumaci, \u201cSPE-LC\/MS Bioanalytical Quantification of the Biotherapeutic Peptide, Semaglutide From Plasma.\u201d Accessed: Apr. 05, 2025. [Online]. Available: https:\/\/www.waters.com\/nextgen\/us\/en\/library\/application-notes\/2023\/spe-lc-msbioanalytical-quantification-of-the-biotherapeutic-peptide-semaglutide-from-plasma.html."},{"key":"10.1016\/j.ejpb.2025.114780_b0090","unstructured":"T. Datar, S. Gawande, P. Wagh, and A. Bartlett, \u201cQuantification of Semaglutide in Human Plasma Using Xevo TM TQ-XS Mass Spectrometer: A Highly Sensitive and Reliable Analytical Method,\u201d no. Cv, pp. 1\u201314."},{"key":"10.1016\/j.ejpb.2025.114780_b0095","unstructured":"M. Trudeau and A. Scumaci, \u201cSPE-LC \/ MS Bioanalytical Quantification of the Biotherapeutic Peptide, Semaglutide From Plasma,\u201d pp. 1\u201314, 2023."},{"key":"10.1016\/j.ejpb.2025.114780_b0100","unstructured":"\u201cSemaglutide Impurities,\u201d SynZeal Research Pvt Ltd, 2025. Accessed: Apr. 07, 2025. [Online]. Available: https:\/\/www.synzeal.com\/en\/semaglutide."},{"issue":"18","key":"10.1016\/j.ejpb.2025.114780_b0105","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2025.114780_b0110","unstructured":"\u201cSemaglutide-Pharmaceutical Reference Standards - Impurity Standards,\u201d SimSon Pharma. Accessed: Apr. 07, 2025. [Online]. Available: https:\/\/www.simsonpharma.com\/promotions\/semaglutide-impurities."},{"key":"10.1016\/j.ejpb.2025.114780_b0115","unstructured":"\u201cSemaglutide Impurities Manufacturers & Suppliers - Daicel Pharma Standards,\u201d Daicel Chiral Technologies (India) Pvt. Ltd. Accessed: Apr. 07, 2025. [Online]. Available: https:\/\/www.daicelpharmastandards.com\/product-category\/semaglutide\/."},{"key":"10.1016\/j.ejpb.2025.114780_b0120","unstructured":"\u201cSemaglutide Impurities | Pharmaffiliates,\u201d Pharmaffiliates. Accessed: Apr. 05, 2025. [Online]. Available: https:\/\/www.pharmaffiliates.com\/en\/parentapi\/semaglutide-impurities."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114780_b0125","doi-asserted-by":"crossref","DOI":"10.1098\/rsfs.2017.0030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics","volume":"7","author":"Zapadka","year":"2017","journal-title":"Interface Focus"},{"key":"10.1016\/j.ejpb.2025.114780_b0130","series-title":"Evaluation of the stability of exenatide in aqueous solutions","author":"Assadi","year":"2015"},{"issue":"8","key":"10.1016\/j.ejpb.2025.114780_b0135","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/pharmaceutics13081263","article-title":"The effects of pH and excipients on exenatide stability in solution","volume":"13","author":"Benet","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2025.114780_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","article-title":"Disulfide bond structures of IgG molecules","volume":"4","author":"Liu","year":"2012","journal-title":"MAbs"},{"issue":"15","key":"10.1016\/j.ejpb.2025.114780_b0145","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.addr.2010.04.002","article-title":"Applications of elastin-like polypeptides in tissue engineering","volume":"62","author":"Nettles","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.ejpb.2025.114780_b0150","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.98.3.944","article-title":"Molecular clocks","volume":"98","author":"Robinson","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.ejpb.2025.114780_b0155","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s11095-022-03265-3","article-title":"Design and development of a new glucagon-like peptide-1 receptor agonist to obtain high oral bioavailability","volume":"39","author":"Chen","year":"2022","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.ejpb.2025.114780_b0160","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bpj.2015.07.051","article-title":"Oligomerization of a glucagon-like peptide 1 analog: Bridging experiment and simulations","volume":"109","author":"Frederiksen","year":"2015","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejpb.2025.114780_b0165","unstructured":"USFDA, \u201cCENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 213051Orig1s000 PRODUCT QUALITY REVIEW(S)\u201d."},{"issue":"1","key":"10.1016\/j.ejpb.2025.114780_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-Hydroxylbenzoyl] Amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience","volume":"42","author":"Solis-Herrera","year":"2024","journal-title":"Clin. Diabetes"},{"issue":"2","key":"10.1016\/j.ejpb.2025.114780_b0175","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40268-021-00341-8","article-title":"A review on the efficacy and safety of oral semaglutide","volume":"21","author":"Niman","year":"2021","journal-title":"Drugs R. D."},{"issue":"468","key":"10.1016\/j.ejpb.2025.114780_b0180","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpb.2025.114780_b0185","article-title":"Effect of lipidation on the structure, oligomerization, and aggregation of glucagon-like peptide 1","author":"Brichtov\u00e1","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejpb.2025.114780_b0190","unstructured":"A. Benet, \u201cUsing Forced Degradation to Aid the Development of Biopharmaceutical Products,\u201d 2021, https:\/\/doi.org\/10.7302\/2763."},{"issue":"4","key":"10.1016\/j.ejpb.2025.114780_b0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1007\/s11095-009-0045-6","article-title":"Stability of protein pharmaceuticals: an update","volume":"27","author":"Manning","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2025.114780_b0200","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-152808-9.50013-4","article-title":"Deamidation of glutaminyl and asparaginyl residues in peptides and proteins","volume":"8","author":"Robinson","year":"1974","journal-title":"Curr. Top. Cell. Regul."},{"issue":"2","key":"10.1016\/j.ejpb.2025.114780_b0205","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0378-5173(99)00152-0","article-title":"Instability, stabilization, and formulation of liquid protein pharmaceuticals","volume":"185","author":"Wang","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2025.114780_b0210","article-title":"Confirmation of peptide-related impurity intact mass using agilent 1290 infinity II bio 2D-LC and infinitylab LC \/ MSD XT","author":"Ryu","year":"2024","journal-title":"Agillent Technology"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641125001572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:11:29Z","timestamp":1753974689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641125001572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"alternative-id":["S0939641125001572"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114780","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2025.114780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114780"}}